Abstract

Background

although type 2 diabetes increases risk of dementia by 2-fold, whether optimizing glycemic level in late life can reduce risk of dementia remains uncertain. We examined if achieving the glycemic goal recommended by the American Diabetes Association (ADA) within a year was associated with lower risk of dementia in 6 years.

Methods

in this population-based observational study, we examined 2246 community-living dementia-free Chinese older adults with type 2 diabetes who attended the Elderly Health Centres in Hong Kong at baseline and followed their HbA1c level and cognitive status for 6 years. In line with the ADA recommendation, we defined the glycemic goal as HbA1c < 7.5%. The study outcome was incident dementia in 6 years, diagnosed according to the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10) or Clinical Dementia Rating of 1–3.

Results

those with HbA1c ≥ 7.5% at baseline and HbA1c < 7.5% in 1 year were associated with higher rather than lower incidence of dementia, independent of severe hypoglycemia, glycemic variability and other health factors. Sensitivity analyses showed that a relative reduction of ≥10%, but not 5–10%, in HbA1c within a year was associated with higher incidence of dementia in those with high (≥8%) and moderate (6.5–7.9%) HbA1c at baseline.

Conclusion

a large reduction in HbA1c could be a potential predictor and possibly a risk factor for dementia in older adults with type 2 diabetes. Our findings suggest that optimizing or intensifying glycemic control in this population requires caution.

Key points

  • A large drop in HbA1c might be an important factor in the development of dementia in older adults with type 2 diabetes.

  • Optimizing or intensifying glycemic control in this population requires caution.

  • Older adults with a significant decrease in HbA1c might warrant further clinical risk assessment for cognitive impairment.

Introduction

Dementia is a global health problem. Dementia prevention is particularly important to people with type 2 diabetes because their number is growing [1], and they are twice as likely to develop dementia as those without [2]. One possible mechanism underlying higher dementia risk in diabetes is hyperglycemia [2–4]. While higher HbA1c is associated with higher dementia risk [5–8], it is unclear whether improving glycemic control could reduce the risk. With evidence suggesting that intensive glycemic lowering might paradoxically elevate risks of morbidities and mortality [9–11], studies that examine optimizing glycemic level and the associated risk of dementia are much needed.

In this study, we followed the glycemic level and cognitive status of community-living dementia-free older adults with type 2 diabetes and examined the association of glycemic changes in 1 year with risk of dementia in 6 years. We hypothesized that maintaining HbA1c above the glycemic target recommended by the American Diabetes Association (ADA) was associated with higher dementia risk, whereas achieving the target within a year was associated with lower risk. Our findings might support and extend the previous literature that hyperglycemia is important to the development of dementia, and optimizing glycemic level, even in late life, can help prevent dementia.

Methods

Study design, setting and participants

This longitudinal observational study was based on all individuals aged 65 and older who completed baseline assessment at the Elderly Health Centres (EHCs) of the Department of Health of the Government of Hong Kong in the first 6 months of 2005 (N = 18,298). Inclusion criteria for this study were Chinese ethnicity, living in the community and having known type 2 diabetes. Exclusion criteria were living in nursing homes; diagnosis of type 2 diabetes not confirmed by physicians; having stroke, Parkinson’s disease, or clinical dementia or scoring below the education-specific cutoff on the Cantonese version of the Mini-Mental State Examination (C-MMSE) at baseline [12]. Participants were followed up at the EHCs for 6 years to the outcome of incident dementia. Those who missed the follow-up assessments were traced and interviewed by geriatric psychiatrists at home, and the names of those not traceable were verified with the Deaths Registry.

Assessment of glycemic control

At baseline and follow-up, HbA1c was measured in whole blood sample with the High Performance Liquid Chromatography at the Public Health Laboratory Centre of the Department of Health. All HbA1c measurements were in the Diabetes Control and Complications Trial units (%). Following the ADA recommendation, optimal glycemic control was defined as HbA1c < 7.5% [13].

As glycemic variability is a potential risk factor for dementia independent of hyperglycemia [14], the intra-individual mean (HbA1c-MEAN), standard deviation (HbA1c-SD) and coefficient of variation (HbA1c-CV) of HbA1c were calculated for each participant. HbA1c-CV, defined as the ratio of HbA1c-SD to HbA1c-MEAN, serves as a better marker for glycemic variability because it corrects for the larger SDs due to higher absolute values of HbA1c-MEAN [15].

With the possible link between severe hypoglycemia and dementia [16, 17], we also reviewed the number of hospital admissions, including attendance to the emergency department, and duration of stay for each participant.

Identification of dementia cases

At baseline and follow-up, participants underwent comprehensive cognitive assessments by the EHC physicians, including a detailed history, the Abbreviated Mental Test and the C-MMSE. Those interviewed by geriatric psychiatrists received the C-MMSE, clinical examination and Clinical Dementia Rating (CDR). A clinical diagnosis of dementia was made according to the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10) or CDR of 1–3 [18].

Assessment of other variables

Demographics (age, sex, educational level and socioeconomic status), physical and psychiatric comorbidities (hypertension, hypercholesterolemia, obesity, heart diseases, visual and hearing impairments, poor mobility, poor balance and depression), physical health parameters (blood pressure, fasting total cholesterol level and body mass index [BMI]) and lifestyle behaviors (physical and intellectual activities, and smoking) were examined during the assessment. All diseases were verified by physicians according to ICD-10. Obesity was defined as BMI ≥ 25 kg/m2 according to the Asian references [19]. Visual and hearing impairments, poor mobility and balance, physical and intellectual activities and smoking were defined as previously reported [20–22]. Low socioeconomic status was defined as receiving social security from the government.

Flowchart of the participants in the study.
Figure 1

Flowchart of the participants in the study.

Statistical analysis

Sample size estimation is available in Supplementary data, Appendix 1, in Age and Ageing online [23].

Statistical analysis was performed using IBM SPSS Statistics, version 24.0 (IBM Corp). Continuous and categorical variables were compared between participants with and without incident dementia by the independent t-test and the Chi-squared (χ2) test, respectively. The level of statistical significance was set at P < 0.05 (2-tailed). The proportion of participants with HbA1c ≥ 7.5% over the first year was compared between those with and without incident dementia. Sensitivity analyses were performed to test if higher dementia incidence was observed in those with less stringent glycemic control (HbA1c ≥ 8.5%) and in those with larger glycemic variability over the first year. To test if optimizing glycemic level was associated with lower dementia incidence, the proportion of participants with HbA1c ≥ 7.5% at baseline but <7.5% by the end of Year 1 was compared between those with and without incident dementia. Multivariable logistic regression analysis was performed to test if the observed association remained robust after adjusting for glycemic variability, severe hypoglycemic episodes, cardiovascular risk factors, physical health parameters, physical impairments, depression, sociodemographic factors and lifestyle behaviors. The odds ratios (ORs) were computed to yield point estimates with 95% confidence intervals (95% CIs). To ascertain that the risk of incident dementia was associated with glycemic changes over the first year rather than changes in the following years, the analyses were repeated by additionally adjusting for the HbA1c-MEAN, HbA1c-SD and HbA1c-CV from the first year to the year of assessment when the participant was found to have dementia or to the year of last assessment if the participant remained free of dementia.

Given the possible U-shaped association between glycemic level and dementia risk [24], sensitivity analyses were conducted to examine the association of HbA1c changes with dementia incidence while considering the baseline HbA1c level. Stratification of HbA1c changes was based on (i) different tertiles of HbA1c level at baseline—HbA1c below the 25th percentile (<6.5%), between the 25th and 75th percentiles (6.5–7.9%) and above the 75th percentile (≥8.0%) were regarded as low, moderate and high level, respectively and (ii) the relative changes of HbA1c levels from baseline to Year 1—<−10%, −10% to +10% and ≥+10% over the first year were regarded as a decreasing, stable and increasing trend, respectively. The moderate-stable category served as reference for comparison with the others. To test if the association remained robust with milder HbA1c changes, the analyses were repeated with relatively smaller changes in HbA1c (5–10%) over the first year.

Table 1

Comparison of baseline characteristics between older adults with type 2 diabetes with and without incident dementia in 6 years.

CharacteristicIncident dementiaP value
No (n = 2004)Yes (n = 242)
HbA1c, %7.3 ± 1.37.4 ± 1.30.50*
   HbA1c ≥ 7.5%, n (%)772 (38.5)92 (38.0)0.88
   HbA1c ≥ 8.5%, n (%)277 (13.8)41 (16.9)0.19
Hospital admissions, episodes0.2 ± 0.50.2 ± 0.40.42*
Age, years74.4 ± 4.677.0 ± 4.9<0.001*
Female, n (%)1218 (60.8)182 (75.2)<0.001
No schooling received, n (%)529 (26.4)99 (40.9)<0.001
Low socioeconomic class, n (%)258 (12.9)39 (16.1)0.16
Hypertension, n (%)1535 (76.6)199 (82.2)<0.05
Systolic blood pressure, mm Hg144 ± 21143 ± 190.66*
Diastolic blood pressure, mm Hg71 ± 1070 ± 110.05*
Hypercholesterolemia, n (%)805 (40.2)87 (36.0)0.21
Fasting total cholesterol, mmol/L5.2 ± 1.05.3 ± 1.00.75*
Obesity, n (%)877 (43.8)114 (47.1)0.32
BMI, kg/m224.8 ± 3.325.0 ± 3.70.36*
Heart diseases, n (%)273 (13.6)39 (16.1)0.29
Visual impairment, n (%)198 (9.9)37 (15.3)0.009
Hearing impairment, n (%)478 (23.9)57 (23.6)0.92
Poor mobility, n (%)181 (9.0)35 (14.5)0.007
Poor balance, n (%)499 (24.9)86 (35.5)<0.001
Depression, n (%)85 (4.2)14 (5.8)0.27
Physical exercise, n (%)592 (29.5)54 (22.3)0.02
Intellectual activities, n (%)1322 (66.0)120 (49.6)<0.001
Smoking, n (%)102 (5.1)8 (3.3)0.22
CharacteristicIncident dementiaP value
No (n = 2004)Yes (n = 242)
HbA1c, %7.3 ± 1.37.4 ± 1.30.50*
   HbA1c ≥ 7.5%, n (%)772 (38.5)92 (38.0)0.88
   HbA1c ≥ 8.5%, n (%)277 (13.8)41 (16.9)0.19
Hospital admissions, episodes0.2 ± 0.50.2 ± 0.40.42*
Age, years74.4 ± 4.677.0 ± 4.9<0.001*
Female, n (%)1218 (60.8)182 (75.2)<0.001
No schooling received, n (%)529 (26.4)99 (40.9)<0.001
Low socioeconomic class, n (%)258 (12.9)39 (16.1)0.16
Hypertension, n (%)1535 (76.6)199 (82.2)<0.05
Systolic blood pressure, mm Hg144 ± 21143 ± 190.66*
Diastolic blood pressure, mm Hg71 ± 1070 ± 110.05*
Hypercholesterolemia, n (%)805 (40.2)87 (36.0)0.21
Fasting total cholesterol, mmol/L5.2 ± 1.05.3 ± 1.00.75*
Obesity, n (%)877 (43.8)114 (47.1)0.32
BMI, kg/m224.8 ± 3.325.0 ± 3.70.36*
Heart diseases, n (%)273 (13.6)39 (16.1)0.29
Visual impairment, n (%)198 (9.9)37 (15.3)0.009
Hearing impairment, n (%)478 (23.9)57 (23.6)0.92
Poor mobility, n (%)181 (9.0)35 (14.5)0.007
Poor balance, n (%)499 (24.9)86 (35.5)<0.001
Depression, n (%)85 (4.2)14 (5.8)0.27
Physical exercise, n (%)592 (29.5)54 (22.3)0.02
Intellectual activities, n (%)1322 (66.0)120 (49.6)<0.001
Smoking, n (%)102 (5.1)8 (3.3)0.22

*mean ± standard deviation for continuous variables as determined by the independent t-test.

n (%) for categorical variables as determined by the χ2 test.

Table 1

Comparison of baseline characteristics between older adults with type 2 diabetes with and without incident dementia in 6 years.

CharacteristicIncident dementiaP value
No (n = 2004)Yes (n = 242)
HbA1c, %7.3 ± 1.37.4 ± 1.30.50*
   HbA1c ≥ 7.5%, n (%)772 (38.5)92 (38.0)0.88
   HbA1c ≥ 8.5%, n (%)277 (13.8)41 (16.9)0.19
Hospital admissions, episodes0.2 ± 0.50.2 ± 0.40.42*
Age, years74.4 ± 4.677.0 ± 4.9<0.001*
Female, n (%)1218 (60.8)182 (75.2)<0.001
No schooling received, n (%)529 (26.4)99 (40.9)<0.001
Low socioeconomic class, n (%)258 (12.9)39 (16.1)0.16
Hypertension, n (%)1535 (76.6)199 (82.2)<0.05
Systolic blood pressure, mm Hg144 ± 21143 ± 190.66*
Diastolic blood pressure, mm Hg71 ± 1070 ± 110.05*
Hypercholesterolemia, n (%)805 (40.2)87 (36.0)0.21
Fasting total cholesterol, mmol/L5.2 ± 1.05.3 ± 1.00.75*
Obesity, n (%)877 (43.8)114 (47.1)0.32
BMI, kg/m224.8 ± 3.325.0 ± 3.70.36*
Heart diseases, n (%)273 (13.6)39 (16.1)0.29
Visual impairment, n (%)198 (9.9)37 (15.3)0.009
Hearing impairment, n (%)478 (23.9)57 (23.6)0.92
Poor mobility, n (%)181 (9.0)35 (14.5)0.007
Poor balance, n (%)499 (24.9)86 (35.5)<0.001
Depression, n (%)85 (4.2)14 (5.8)0.27
Physical exercise, n (%)592 (29.5)54 (22.3)0.02
Intellectual activities, n (%)1322 (66.0)120 (49.6)<0.001
Smoking, n (%)102 (5.1)8 (3.3)0.22
CharacteristicIncident dementiaP value
No (n = 2004)Yes (n = 242)
HbA1c, %7.3 ± 1.37.4 ± 1.30.50*
   HbA1c ≥ 7.5%, n (%)772 (38.5)92 (38.0)0.88
   HbA1c ≥ 8.5%, n (%)277 (13.8)41 (16.9)0.19
Hospital admissions, episodes0.2 ± 0.50.2 ± 0.40.42*
Age, years74.4 ± 4.677.0 ± 4.9<0.001*
Female, n (%)1218 (60.8)182 (75.2)<0.001
No schooling received, n (%)529 (26.4)99 (40.9)<0.001
Low socioeconomic class, n (%)258 (12.9)39 (16.1)0.16
Hypertension, n (%)1535 (76.6)199 (82.2)<0.05
Systolic blood pressure, mm Hg144 ± 21143 ± 190.66*
Diastolic blood pressure, mm Hg71 ± 1070 ± 110.05*
Hypercholesterolemia, n (%)805 (40.2)87 (36.0)0.21
Fasting total cholesterol, mmol/L5.2 ± 1.05.3 ± 1.00.75*
Obesity, n (%)877 (43.8)114 (47.1)0.32
BMI, kg/m224.8 ± 3.325.0 ± 3.70.36*
Heart diseases, n (%)273 (13.6)39 (16.1)0.29
Visual impairment, n (%)198 (9.9)37 (15.3)0.009
Hearing impairment, n (%)478 (23.9)57 (23.6)0.92
Poor mobility, n (%)181 (9.0)35 (14.5)0.007
Poor balance, n (%)499 (24.9)86 (35.5)<0.001
Depression, n (%)85 (4.2)14 (5.8)0.27
Physical exercise, n (%)592 (29.5)54 (22.3)0.02
Intellectual activities, n (%)1322 (66.0)120 (49.6)<0.001
Smoking, n (%)102 (5.1)8 (3.3)0.22

*mean ± standard deviation for continuous variables as determined by the independent t-test.

n (%) for categorical variables as determined by the χ2 test.

Results

Incidence of dementia

A total of 2246 were included into this study (Figure 1). They had a median follow-up period of 5.0 years. Total of 297 (13.2%) participants were dead, and 242 (10.8%) had incident dementia in 6 years. Those who developed dementia were predominantly female and older, with lower educational attainment, more physical co-morbidities and less healthy lifestyle practices (Table 1).

Table 2

Estimated ORs and 95% CI for incident dementia among older adults who had type 2 diabetes and were free of dementia

HbA1c trajectory*Model 1Model 2
OR (95% CI)P valueOR (95% CI)P value
Low and stable1.39 (0.77–2.50)0.281.20 (0.63–2.29)0.58
Low and increasing0.86 (0.35–2.13)0.750.76 (0.27–2.13)0.61
Moderate and decreasing3.50 (1.41–8.70)0.0073.24 (1.13–9.24)0.03
Moderate and increasing1.51 (0.83–2.76)0.431.35 (0.69–2.64)0.37
High and decreasing2.36 (1.27–4.40)0.0072.76 (1.39–5.47)0.004
High and stable1.52 (0.84–2.76)0.171.46 (0.77–2.75)0.25
High and increasing2.63 (1.13–6.12)0.022.82 (1.05–7.59)0.04
HbA1c trajectory*Model 1Model 2
OR (95% CI)P valueOR (95% CI)P value
Low and stable1.39 (0.77–2.50)0.281.20 (0.63–2.29)0.58
Low and increasing0.86 (0.35–2.13)0.750.76 (0.27–2.13)0.61
Moderate and decreasing3.50 (1.41–8.70)0.0073.24 (1.13–9.24)0.03
Moderate and increasing1.51 (0.83–2.76)0.431.35 (0.69–2.64)0.37
High and decreasing2.36 (1.27–4.40)0.0072.76 (1.39–5.47)0.004
High and stable1.52 (0.84–2.76)0.171.46 (0.77–2.75)0.25
High and increasing2.63 (1.13–6.12)0.022.82 (1.05–7.59)0.04

*Comparison was made with the moderate and stable HbA1c trajectory.

Adjusted for severe hypoglycemic episodes, sociodemographic factors, cardiovascular risk factors, physical health parameters, physical impairments, depression and lifestyle behaviors.

Table 2

Estimated ORs and 95% CI for incident dementia among older adults who had type 2 diabetes and were free of dementia

HbA1c trajectory*Model 1Model 2
OR (95% CI)P valueOR (95% CI)P value
Low and stable1.39 (0.77–2.50)0.281.20 (0.63–2.29)0.58
Low and increasing0.86 (0.35–2.13)0.750.76 (0.27–2.13)0.61
Moderate and decreasing3.50 (1.41–8.70)0.0073.24 (1.13–9.24)0.03
Moderate and increasing1.51 (0.83–2.76)0.431.35 (0.69–2.64)0.37
High and decreasing2.36 (1.27–4.40)0.0072.76 (1.39–5.47)0.004
High and stable1.52 (0.84–2.76)0.171.46 (0.77–2.75)0.25
High and increasing2.63 (1.13–6.12)0.022.82 (1.05–7.59)0.04
HbA1c trajectory*Model 1Model 2
OR (95% CI)P valueOR (95% CI)P value
Low and stable1.39 (0.77–2.50)0.281.20 (0.63–2.29)0.58
Low and increasing0.86 (0.35–2.13)0.750.76 (0.27–2.13)0.61
Moderate and decreasing3.50 (1.41–8.70)0.0073.24 (1.13–9.24)0.03
Moderate and increasing1.51 (0.83–2.76)0.431.35 (0.69–2.64)0.37
High and decreasing2.36 (1.27–4.40)0.0072.76 (1.39–5.47)0.004
High and stable1.52 (0.84–2.76)0.171.46 (0.77–2.75)0.25
High and increasing2.63 (1.13–6.12)0.022.82 (1.05–7.59)0.04

*Comparison was made with the moderate and stable HbA1c trajectory.

Adjusted for severe hypoglycemic episodes, sociodemographic factors, cardiovascular risk factors, physical health parameters, physical impairments, depression and lifestyle behaviors.

Glycemic control over the first year

The mean HbA1c at baseline was not significantly different between participants with and without incident dementia (Table 1). Neither those with HbA1c ≥ 7.5% nor those with HbA1c ≥ 8.5% at baseline (Table 1) or over the first year (see Supplementary Table 1 available in Age and Ageing online) were significantly more prevalent in the incident dementia group. HbA1c variability over the first year was not significantly different between the two groups (see Supplementary Table 2 available in Age and Ageing online).

Interestingly, the proportion of those with HbA1c ≥ 7.5% at baseline but <7.5% by Year 1 was higher in the incident dementia group than in the cognitively stable group (20 [8.3%] vs. 117 [5.8%]; P = 0.14). The OR for incident dementia was 1.92 (95% CI = 1.05–3.52; P = 0.03) after controlling for HbA1c-CV, severe hypoglycemic episodes, physical, psychosocial and lifestyle factors. The association remained significant after additional adjustment for HbA1c-MEAN (OR = 2.02; 95% CI = 1.03–3.98; P = 0.04), HbA1c-SD (OR = 2.10; 95% CI = 1.03–4.41; P < 0.05) and HbA1c-CV (OR = 2.10; 95% CI = 1.00–4.39; P < 0.05) over subsequent years.

Different categories of glycemic control

Sensitivity analyses showed that HbA1c changes were associated with dementia incidence after considering the baseline HbA1c level (Table 2). The high-increasing category was more prevalent in the incident dementia group (8 of 65 [12.3%] vs. 41 of 535 [7.7%]; P = 0.20), with an OR of 2.82 (95% CI = 1.05–7.59; P = 0.04).

Interestingly, the high-decreasing category was also more prevalent in the incident dementia group (18 of 75 [24.0%] vs. 103 of 597 [17.3%]; P = 0.15), with an OR of 2.76 (95% CI = 1.39–5.47; P = 0.004). Association with higher dementia incidence was not observed in participants with milder decrease in HbA1c over the first year (9 of 50 [18.0%] vs. 53 of 366 [14.5%]; P = 0.51).

The moderate-decreasing category was more prevalent in the incident dementia group (7 of 64 [10.9%] vs. 27 of 521 [5.2%]; P = 0.06), with an OR of 3.24 (95% CI = 1.13–9.24; P = 0.03). Those with milder decrease in HbA1c over the first year were more prevalent in the cognitively stable group, but the OR did not reach statistical significance (OR = 0.33; 95% CI = 0.39–2.70; P = 0.30).

Although the OR for dementia was greater than 1 in the low-stable, moderate-increasing and high-stable categories and less than 1 in the low-increasing category, none reached statistical significance (Table 2). The OR was not computed for the low-decreasing category due to limited number of participants.

Discussion

While high and increasing HbA1c was associated with higher dementia incidence, we found that achieving the glycemic goal within a year was associated with higher rather than lower dementia incidence, independent of severe hypoglycemia, glycemic variability and other physical, psychosocial and lifestyle factors. This association was observed in both high (≥8%) and moderate HbA1c (6.5–7.9%) at baseline followed by a large drop (a relative reduction of ≥10%), but not milder decrease (a relative reduction of 5–10%), within a year. Our findings suggest that the rate of decline in glycemic level might be an important factor in the development of dementia in older adults with diabetes, and from a clinical perspective, healthcare professionals need to be mindful of older adults who experience a sudden large drop in HbA1c, be cautious in optimizing glycemic level in those with hyperglycemia, and be aware of the possible elevated risk of dementia in intensifying glycemic control in those not having high HbA1c.

Comparison with other studies

Although previous literature suggests that hyperglycemia is associated with different pathologies of dementia, including altered amyloid metabolism, microvascular changes, insulin dysregulation and changes in insulin and insulin-like growth factor-1 (IGF-1) signaling, overproduction of reactive oxygen species and increased pro-inflammatory cytokines [2–4], we did not find an association between hyperglycemia alone and higher dementia incidence. As the pathologies often take many years, if not decades, to develop, a longer duration of hyperglycemia might be required before dementia risk increases [25]. Alternatively, higher glycemic levels might be needed for dementia to develop [5–8]. Although we did not find such association with HbA1c ≥ 8.5%, we found that worsening of hyperglycemia was associated with higher dementia incidence. This might be explained by an accelerated accumulation of dementia pathologies in the brain, thus advancing the clinical manifestation of dementia.

We did not find lowering glycemic level to the recommended target within a year associating with risk reduction. This is not fully explained by severe hypoglycemia, glycemic variability, or subsequent glycemic changes. It might be that once developed, the dementia pathologies are irreversible, even with improved glycemic control in late life. More importantly, we found that a significant drop in HbA1c was associated with higher dementia risk. While the precise mechanisms remain to be elucidated, we speculate that older adults with hyperglycemia but not yet having dementia may be at the stage when compensatory mechanisms are still functioning, so the detrimental effect of dementia pathologies is moderated, and their cognition maintains relatively unimpaired. However, once the blood glucose level falls too quickly and stays much lower than previously, the abrupt change in glycemic level may predispose the older adults to metabolic dysfunction and abnormal glucose and energy homeostasis in the brain, triggering oxidative stress and inflammation and thereby leading to decompensation and onset of dementia symptoms.

In line with the ADVANCE and ACCORD studies, which did not find intensive glycemic control preventing cognitive decline [9–11], our findings highlight the concern of intensifying glucose lowering in older adults whose HbA1c levels are not particularly high. Indeed, low HbA1c is associated with increased frailty and mortality [26–29]. Differences in other outcomes between the ADVANCE and ACCORD studies, possibly explained by variations in how intensive glycemic control was attained, also highlight the potential importance of the rate of drop in HbA1c as suggested by our findings. It would be important to further examine what the optimal glycemic target for older adults should be, and how it should be achieved, so that the risk of diabetic complications can be minimized without adversely affecting cognition.

Limitations and strengths

Given the nature of our study design, care should be taken when making an inference about a causal relationship between glycemic changes and dementia risk. The possibility of reverse causation could not be completely excluded because the baseline cognitive capacity and the onset, duration and treatment of diabetes were not assessed [25]. Although our participants were screened negative for significant cognitive impairment at baseline, the potential confounding problems of people having poorer treatment compliance and suboptimal glycemic control owing to subtle cognitive impairment might still be present. For logistic reasons, examination of other diabetes-related complications, mild or asymptomatic hypoglycemic episodes, and daily glycemic variability, detailed neuropsychological assessments, genotyping and brain imaging were not conducted. Given the studies showing that significant hypoglycemia is associated with the development of dementia [16, 17] and the problem that hypoglycemia is often asymptomatic in older people, asymptomatic or mildly symptomatic hypoglycemia might contribute to the link found between the rapid decline in HbA1c and development of dementia. Moreover, categorizing baseline HbA1c levels and subsequent changes into different groups might introduce the problems of multiple comparisons and loss of power, though with a P-value of 0.004 in the high-decreasing category type I error is unlikely. Furthermore, direct application of our findings to older populations with more severe diabetes, from later generations, and of other ethnicities requires caution, as our cohort was relatively healthy, had lower educational attainment and were ethnic Chinese, who in general have lower prevalence of Apolipoprotein E4, higher prevalence of hypertension, lower BMI cutoff for obesity and higher susceptibility to developing diabetes at lower BMI [30].

Regarding the strengths of this study, we followed this community cohort for a long time, with measures taken to minimize attrition rate. Dementia was identified from cognitive assessments rather than solely from hospital records. Various health problems and behaviors and diabetes-specific factors, including severe hypoglycemia and glycemic variability, were controlled in the analyses.

Conclusion

With a large decrease in glycemic level being a potential predictor and possibly a risk factor for dementia in older adults with diabetes, our findings suggest the need for being attentive to both increasing and decreasing HbA1c levels, with an emphasis on not only achieving a particular glycemic target but also promoting moderation of glycemic level.

Declaration of Conflicts of Interest

None.

Declaration of Sources of Funding

This work was supported by the Health and Health Services Research Fund of the Government of Hong Kong (grant 09100071), which had no role in the design, execution, analysis and interpretation of data, or writing of the study.

Ethical approval

This study was approved by both the Ethics Committee of the Department of Health of the Government of Hong Kong and the Joint Clinical Research Ethics Committee of the Chinese University of Hong Kong and the Hospital Authority.

Acknowledgment

We thank the staff of the Elderly Health Service for conducting assessment at the EHCs, cross-checking the defaulted participants with the Deaths Registry and providing the anonymized data. We also thank the research assistants (Ada Fung, Shelley Leung, Janette Chow, Alicia Chan, Jeanie Law and Jonathan Liu) for tracing the defaulted participants. Last but not least, we thank the participants and their family members in this study.

References

1.

Boyle
JP
,
Honeycutt
AA
,
Narayan
KM
et al.
Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S
.
Diabetes Care
2001
;
24
:
1936
40
.

2.

Biessels
GJ
,
Staekenborg
S
,
Brunner
E
,
Brayne
C
,
Scheltens
P
.
Risk of dementia in diabetes mellitus: a systematic review
.
Lancet Neurol
2006
;
5
:
64
74
.

3.

Exalto
LG
,
Whitmer
RA
,
Kappele
LJ
,
Biessels
GJ
.
An update of type 2 diabetes, vascular dementia and Alzheimer’s disease
.
Exp Gerontol
2012
;
47
:
858
64
.

4.

McCrimmon
RJ
,
Ryan
CM
,
Frier
BM
.
Diabetes and cognitive dysfunction
.
Lancet
2012
;
379
:
2291
9
.

5.

Lacy
ME
,
Gilsanz
P
,
Karter
AJ
,
Quesenberry
CP
,
Pletcher
MJ
,
Whitmer
RA
.
Long-term glycemic control and dementia risk in type 1 diabetes
.
Diabetes Care
2018
;
41
:
2339
45
.

6.

Rawshani
A
,
Rawshani
A
,
Svensson
AM
,
Gudbjörnsdottir
S
.
Glycaemic control and incidence of dementia in 363,573 patients with type 2 diabetes: an observational study
.
Diabetologia
2015
;
58
:
S5
.

7.

Zheng
F
,
Yan
L
,
Yang
Z
,
Zhong
B
,
Xie
W
.
HbA1c, diabetes and cognitive decline: the English longitudinal study of ageing
.
Diabetologia
2018
;
61
:
839
48
.

8.

Ramirez
A
,
Wolfsgruber
S
,
Lange
C
et al.
Elevated HbA1c is associated with increased risk of incident dementia in primary care patients
.
J Alzheimers Dis
2015
;
44
:
1203
12
.

9.

Action to Control Cardiovascular Risk in Diabetes Study Group
.
Effects of intensive glucose lowering in type 2 diabetes
.
N Engl J Med
2008
;
358
:
2545
59
.

10.

ADVANCE Collaborative Group
.
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
.
N Engl J Med
2008
;
358
:
2560
72
.

11.

Launer
LJ
,
Miller
ME
,
Williamson
JD
et al.
Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy
.
Lancet Neurol
2011
;
10
:
969
77
.

12.

Chiu
HF
,
Lam
LC
,
Chi
I
et al.
Prevalence of dementia in Chinese elderly in Hong Kong
.
Neurology
1998
;
50
:
1002
9
.

13.

American Diabetes Association
.
Standards of medical care in diabetes—2019
.
Diabetes Care
2019
;
42
:
S1
193
.

14.

Li
TC
,
Yang
CP
,
Tseng
ST
et al.
Visit-to-visit variations in fasting plasma glucose and HbA1c associated with an increased risk of Alzheimer disease: Taiwan diabetes study
.
Diabetes Care
2017
;
40
:
1210
7
.

15.

Penno
G
,
Solini
A
,
Bonora
E
et al.
HbA1c variability as an independent correlate of nephropathy, but not retinopathy, in patients with type 2 diabetes: the renal insufficiency and cardiovascular events (RIACE) Italian multicenter study
.
Diabetes Care
2013
;
36
:
2301
10
.

16.

Whitmer
RA
,
Karter
AJ
,
Yaffe
K
et al.
Hypoglycemic episodes and risk of dementia in older adults with type 2 diabetes mellitus
.
JAMA
2009
;
301
:
1565
72
.

17.

Yaffe
K
,
Falvey
CM
,
Hamilton
N
et al.
Association between hypoglycemic and dementia in a biracial cohort of older adults with diabetes mellitus
.
JAMA Intern Med
2013
;
173
:
1300
6
.

18.

Morris
JC
.
Clinical dementia rating: a reliable and valid diagnostic and staging measure for dementia of the Alzheimer type
.
Int Psychogeriatr
1997
;
9
:
173
6
.

19.

WHO Expert Consultation
.
Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies
.
Lancet
2004
;
363
:
157
63
.

20.

Lee
AT
,
Richards
M
,
Chan
WC
et al.
Poor balance as a noncognitive predictor of incident dementia
.
J Am Geriatr Soc
2015
;
63
:
1701
2
.

21.

Lee
AT
,
Richards
M
,
Chan
WC
et al.
Intensity and types of physical exercise in relation to dementia risk reduction in community-living older adults
.
J Am Med Dir Assoc
2015
;
16
:
899.e1
7
.

22.

Lee
AT
,
Richards
M
,
Chan
WC
et al.
Association of daily intellectual activities with lower risk of incident dementia among Chinese older adults
.
JAMA Psychiat
2018
;
75
:
697
703
.

23.

Mayeda
ER
,
Karter
AJ
,
Huang
ES
et al.
Racial/ethnic differences in dementia risk among older type 2 diabetic patients: the diabetes and aging study
.
Diabetes Care
2014
;
37
:
1009
15
.

24.

Crane
PK
,
Walker
R
,
Hubbard
RA
et al.
Glucose levels and risk of dementia
.
N Engl J Med
2013
;
369
:
540
8
.

25.

Gottesman
RF
,
Albert
MS
,
Alonso
A
et al.
Associations between midlife vascular risk factors and 25-year incident dementia in the atherosclerosis risk in communities (ARIC) cohort
.
JAMA Neurol
2017
;
74
:
1246
54
.

26.

Zaslavsky
O
,
Walker
RL
,
Crane
PK
,
Gray
SL
,
Larson
EB
.
Glucose levels and risk of frailty
.
J Gerontol A Biol Sci Med Sci
2016
;
71
:
1223
9
.

27.

Cavero-Redondo
I
,
Peleteiro
B
,
Álvarez-Bueno
C
,
Rodriguez-Artalejo
F
,
Martínex-Vizcaíno
V
.
Glycated haemoglobin A1c as a risk factor of cardiovascular outcomes and all-cause mortality in diabetic and non-diabetic populations: a systematic review and meta-analysis
.
BMJ Open
2017
;
7
:
e015949
.

28.

Forbes
A
,
Murrells
T
,
Mulnier
H
,
Sinclair
AJ
.
Mean HbA1c, HbA1c variability, and mortality in people with diabetes aged 70 years and older: a retrospective cohort study
.
Lancet Diabetes Endocrinol
2018
;
6
:
476
86
.

29.

Kirkman
MS
,
Mahmud
H
,
Korytkowski
MT
.
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes mellitus
.
Endocrinol Metab Clin North Am
2018
;
47
:
81
96
.

30.

Chan
JC
,
Malik
V
,
Jia
W
et al.
Diabetes in Asia: epidemiology, risk factors, and pathophysiology
.
JAMA
2009
;
301
:
2129
40
.

This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)

Supplementary data

Comments

2 Comments
Comment on: Higher dementia incidence in older adults with type 2 diabetes and large reduction in HbA1c
9 April 2020
Cédric MAHIAT (1), MD, Antoine CHRISTIAENS (2,3), MD, Benoît BOLAND (1,3), MD, PhD
(1) Geriatric medicine department, Cliniques universitaires Saint-Luc, Belgium. (2) Fund for Scientific Research (F.R.S.-FNRS), Belgium. (3) Institute of Health and Society (IRSS), UCL, Belgium
Comment on: Higher dementia incidence in older adults with type 2 diabetes and large reduction in HbA1c

Cédric MAHIAT (1), MD, Antoine CHRISTIAENS (2,3), MD, Benoît BOLAND (1,3), MD, PhD

(1) Geriatric medicine department, Cliniques universitaires Saint-Luc, Brussels, Belgium.
(2) Fund for Scientific Research (F.R.S.-FNRS), Belgium.
(3) Institute of Health and Society (IRSS), Université catholique de Louvain, Brussels, Belgium.

To the editors.

The study of T.C. Lee et al. about dementia incidence in older adults with type 2 diabetes [1] highlights the everyday challenge of physicians who treat type 2 diabetes in older patients: is the standard HbA1c target appropriate for each patient? Is reaching it associated with good clinical outcomes? How intense has to be the treatment to lower HbA1c? According to T.C. Lee et al., a too intense glycaemic control could increase the risk of dementia [1].

We would like to discuss some limitations of this retrospective study of a cohort followed in Hong Kong.

Firstly, 488 of the 2246 participants (22%) were lost to follow-up. The number of the participants lost to follow-up who developed a dementia is unknown. Surprisingly, all these participants were assimilated to the group without incident dementia. The incidence of dementia was thus underestimated.

Secondly, the authors did not analyse the impact of diabetes duration and of glucose-lowering therapy. Yet, if one of the potential mechanisms that increases dementia incidence in patients with diabetes is mediated by hyperglycaemia [2], a long history of diabetes could have led to a higher risk of dementia. Diabetes treatment is also important, as hypoglycaemia is induced by glucose-lowering agents with hypoglycaemic effects and may lead to impaired cognitive functions [3].

Thirdly, the authors report an association between higher dementia rate and large reduction in HbA1c. HbA1c increase was also associated with a higher incidence of dementia (Table 2 in the article [1]). HbA1c variation, more than its reduction, seemed related to dementia in this study. As far as HbA1c reduction is concerned, it is unclear whether this reduction had an impact on cognition or whether the impaired cognitive functions induced the HbA1c reduction. Indeed, participants with mild cognitive impairments at baseline could have been included, because the exclusion criteria had consisted of clinical dementia or a rather elevated C-MMSE score. Therefore, dementia might have been diagnosed in some patients during the follow-up, and might have led to reduced caloric intake, weight loss [4], and a decreasing HbA1c.

Important Hba1c decrease (or variation) may be a cause and an effect of the dementia. Further studies are needed to clarify the direction of this causal relationship. Meanwhile, the study of Lee et al. reminds clinicians that the HbA1c target in older patients with type 2 diabetes needs to be individualised [5].

References :
1. Lee ATC, Richards M, Chan WC et al. Higher dementia incidence in older adults with type 2 diabetes and large reduction in HbA1c. Age Ageing 2019 ; 48(6): 838-844.
2. McCrimmon RJ, Ryan CM, Frier BM. Diabetes and cognitive dysfunction. Lancet 2012 ; 379(9833) : 2291-2299.
3. Ebadi SA, Darvish P, Fard AJ et al. Hypoglycemia and cognitive function in diabetic patients. Diabetes Metab Syndr 2018 ; 12(6) : 893-896.
4. Mitchell SL, Teno JM, Kiely DK et al. The clinical course of advanced dementia. N Engl J Med 2009 ; 361(16) : 1529-1538.
5. Treatment of Diabetes in Older Adults: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2019 ; 104(5): 1520–1574
Submitted on 09/04/2020 9:16 PM GMT
Comment on: Higher dementia incidence in older adults with type 2 diabetes and large reduction in HbA1c
6 January 2020
Bilal KATIPOGLU, Mehmet Ilkin NAHARCI
University of Health Sciences, Gulhane Faculty of Medicine & Gulhane Training and Research Hospital, Division of Geriatrics, Ankara, Turkey
To the Editor: We read with interest the study by T.C. Lee et al. which concluded that a large reduction in glycemic level ispossibly a risk factor for dementia in older adults with diabetes [1]. This paper further highlights the dilemma of geriatricians face in optimizing glycemic control to prevent dementia in diabetic elderly patients. Another important aspect, not frequently discussed in the literature, that should also be addressed, is the intensifying glycemic control in late life. Therefore this study will arouse great interest to researcher in terms of providing insight into the prevention of dementia in this population. On the other hand, a few issues need to be discussed. The authors might not have taken into consideration medications that could have effect on the results, including antidiabetic and anticholinergic drugs.
Medicines with anticholinergic properties have a significant adverse effect on cognitive functions. The negative impact of anticholinergic drugs on cognitive outcomes revealed the strongest association throughout the evidence-base. A recent nested case-control study of 40770 older adults reported that overall anticholinergic exposure might be associated with increased risk of dementia [2]. In a Korean cohort of older people with huge sample size, increased use of strong anticholinergic agents for long periods was associated with a higher risk of dementia [3]. For that reason, anticholinergics seem to interact with dementia among older adults.
A number of studies have provided some evidence of the improvement of cognitive function with antidiabetic drugs. Some oral antidiabetic medications such as metformin, thiazolidinediones, sulphonylureas, dipeptidyl peptidase IV inhibitors (gliptins), glucagon like peptide-1 can improve cognition in patients with dementia [4]. Furthermore, a recent postmortem study showed that the combination of insulin with other diabetic medication in patients with diabetes and dementia was associated with lower neuritic plaque density in hippocampus [5]. These suggest that improvement in cognition with antidiabetic drugs could be a property of the drug rather than pure glycemic control. Therefore, antidiabetic drugs may be covariate factors for prediction on dementia incidence.
Some additional data on anticholinergics and antidiabetics may make the prediction model more accurate to detect the risk of dementia in older diabetic patients. This would provide a better understanding of the link between intensifying glycemic control and the risk of dementia to allow us more accurate clinical judgment.

References
1. Lee, A.T., et al., Higher dementia incidence in older adults with type 2 diabetes and large reduction in HbA1c. Age and Ageing, 2019. 48(6): p. 838-844.
2. Richardson, K., et al., Anticholinergic drugs and risk of dementia: case-control study. bmj, 2018. 361: p. k1315.
3. Joung, K.-i., et al., Association of Anticholinergic Use with Incidence of Alzheimer’s Disease: population-based Cohort study. Scientific reports, 2019. 9(1): p. 6802.
4. Alagiakrishnan, K., et al., Antidiabetic drugs and their potential role in treating mild cognitive impairment and Alzheimer’s disease. Discovery medicine, 2013. 16(90): p. 277-286.
5. Beeri, M., et al., Insulin in combination with other diabetes medication is associated with less Alzheimer neuropathology. Neurology, 2008. 71(10): p. 750-757.
Submitted on 06/01/2020 12:23 PM GMT
Submit a comment
You have entered an invalid code
Thank you for submitting a comment on this article. Your comment will be reviewed and published at the journal's discretion. Please check for further notifications by email.